NCT00400829View on ClinicalTrials.gov

E7389 in Treating Patients With Recurrent or Progressive Stage IIIB or Stage IV Non-Small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

January 31, 2011

Study Completion Date

January 31, 2011

Conditions
Recurrent Non-small Cell Lung CancerStage IIIB Non-small Cell Lung CancerStage IV Non-small Cell Lung Cancer
Interventions
DRUG

eribulin mesylate

Given IV

Trial Locations (2)

15232

University of Pittsburgh Cancer Institute, Pittsburgh

91010

City of Hope, Duarte

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00400829 - E7389 in Treating Patients With Recurrent or Progressive Stage IIIB or Stage IV Non-Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter